Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody

Trial Profile

Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Expanded access; Therapeutic Use
  • Acronyms CheckMate 168
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 28 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 22 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top